Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015

被引：0
|
作者：
Osmolovskaya, Yu. F. [1 ]
Zhirov, I. V. [1 ]
Tereshchenko, S. N. [1 ]
机构：
[1] Minist Hlth Russia, AL Myasnikov Inst Clin Cardiol, Dept Myocardial Dis & Heart Failure, Russian Cardiol Res & Prod Complex, Moscow, Russia
来源：
TERAPEVTICHESKII ARKHIV | 2015年 / 87卷 / 09期
关键词：
aldosterone; mineralocorticoid receptor antagonists; chronic heart failure; PRESERVED EJECTION FRACTION; CHRONIC KIDNEY-DISEASE; SELECTIVE ALDOSTERONE BLOCKER; MILD PATIENTS HOSPITALIZATION; DOUBLE-BLIND; BAY; 94-8862; MYOCARDIAL-INFARCTION; EUROPEAN-SOCIETY; ASSOCIATION HFA; EMPHASIS-HF;
D O I：
10.17116/terarkh201587977-83
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Mineralocorticoid receptor antagonists (MCRA) are part of standard medical therapy for heart failure (HF). The clinical efficacy of MCRA in patients with systolic HF has been proven by randomized clinical trials. The efficacy of this drug group in patients with chronic HF with preserved left ventricular systolic function and the advent and practical introductions of safer new-generation MCRA remain to be answered.
引用
收藏
页码：77 / 83
页数：7
相关论文
共 50 条
  • [1] Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure
    Tereshchenko, S. N.
    Zhirov, I. V.
    Osmolovskaya, Yu F.
    TERAPEVTICHESKII ARKHIV, 2013, 85 (12) : 137 - 143
  • [2] Influence of background treatment with mineralocorticoid receptor antagonists on ivabradines effects in patients with chronic heart failure
    Komajda, Michel
    Boehm, Michael
    Borer, Jeffrey
    Ford, Ian
    Krum, Henry
    Tase, Adrian
    Tavazzi, Luigi
    Swedberg, Karl
    EUROPEAN JOURNAL OF HEART FAILURE, 2013, 15 (01) : 79 - 84
  • [3] Mineralocorticoid receptor antagonists for heart failure
    Richards, Arthur Mark
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (18) : 2801 - 2815
  • [4] Expanding Role of Mineralocorticoid Receptor Antagonists in the Treatment of Heart Failure
    Talatinian, Alidz
    Chow, Sheryl L.
    Heywood, J. Thomas
    PHARMACOTHERAPY, 2012, 32 (09): : 827 - 837
  • [5] Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease
    Khan, Mohammad Saud
    Khan, Muhammad Shahzeb
    Moustafa, Abdelmoniem
    Anderson, Allen S.
    Mehta, Rupal
    Khan, Sadiya S.
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 125 (04): : 643 - 650
  • [6] Study of the effectiveness of mineralocorticoid receptor antagonists on neurohumoral parameters in patients with chronic heart failure
    Kamilova, U. Umida
    Nuritdinov, N.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 361 - 361
  • [7] The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure
    Pitt, Bertram
    Rossignol, Patrick
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (05) : 659 - 665
  • [8] Impact of Mineralocorticoid Receptor Antagonists in the Treatment of Heart Failure: Targeting the Heart Failure Cascade
    Jadhav, Uday
    Nair, Tiny
    Mohanan, Padhinhare
    Chopra, Vijay
    Kerkar, Prafulla
    Das Biswas, Arup
    Hazra, Prakash K.
    Zalte, Nitin
    Sugumaran, Amarnath
    Mohanasundaram, Senthilnathan
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [9] Heart failure: the role for mineralocorticoid receptor antagonists
    Pitt, Bertram
    SWISS MEDICAL WEEKLY, 2014, 144
  • [10] Mineralocorticoid receptor antagonists and acute heart failure
    Escobar, Carlos
    Manzano, Luis
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 (07) : 947 - 947
12345